Thurman Johua M
Department of Medicine, University of Colorado Denver School of Medicine, Denver, CO, USA.
Clin Nephrol. 2012 May;77(5):413-23. doi: 10.5414/cn107220.
Numerous renal diseases are characterized by complement activation within the kidney, and several lines of evidence implicate complement activation as an important part of the pathogenesis of these diseases. Investigators have long anticipated that complement inhibitors would be important and effective therapies for renal diseases. Eculizumab is a monoclonal antibody to the complement protein C5 that has now been administered to patients with several types of renal disease. The apparent efficacy of this agent may herald a new era in the treatment of renal disease, but many questions about the optimal use of therapeutic complement inhibitors remain. Herein we review the rationale for using complement inhibitors in patients with renal disease and discuss several drugs and approaches that are currently under development.
许多肾脏疾病的特征是肾脏内补体激活，并且有几条证据表明补体激活是这些疾病发病机制的重要组成部分。长期以来，研究人员一直预期补体抑制剂将成为治疗肾脏疾病的重要且有效的疗法。依库珠单抗是一种针对补体蛋白C5的单克隆抗体，现已应用于多种类型肾脏疾病的患者。这种药物的明显疗效可能预示着肾脏疾病治疗的新时代，但关于治疗性补体抑制剂的最佳使用仍存在许多问题。在此，我们回顾了在肾脏疾病患者中使用补体抑制剂的基本原理，并讨论了目前正在研发的几种药物和方法。
